Skip to content
Brand AI

Wuchan Zhongda

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2020

    Criticized for exaggerating remdesivir project progress on interactive platform

    During the COVID-19 pandemic, Wuchan Zhongda exaggerated on the "Shanghai Stock Exchange e-Interaction" platform the progress of its participation in a remdesivir-related project, triggering abnormal stock price movements. The Shanghai Stock Exchange issued a public criticism of the company and then board secretary Chen Haibin.

    Source